Biomarkers of sepsis.

Details

Serval ID
serval:BIB_F4175E2DAB90
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Biomarkers of sepsis.
Journal
Critical Care Medicine
Author(s)
Marshall J.C., Reinhart K., International Sepsis Forum
Contributor(s)
International Sepsis Forum, Marshall JC., Reinhart K., Abraham E., Annane D., Calandra T., Cook DJ., Dellinger RP., Dhainaut JF., Hébert P., Heyland D., Moldawer L., Moreno R., Opal S., Stüber F., Vincent JL., Volk HD.
ISSN
1530-0293 (Electronic)
ISSN-L
0090-3493
Publication state
Published
Issued date
2009
Volume
37
Number
7
Pages
2290-2298
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
BACKGROUND: A complex network of biological mediators underlies the clinical syndrome of sepsis. The nonspecific physiologic criteria of sepsis syndrome or the systemic inflammatory response syndrome do not adequately identify patients who might benefit from either conventional anti-infective therapies or from novel therapies that target specific mediators of sepsis. Validated biomarkers of sepsis may improve diagnosis and therapeutic decision making for these high-risk patients.
OBJECTIVES: To develop a methodologic framework for the identification and validation of biomarkers of sepsis.
METHODS: A small group meeting of experts in clinical epidemiology, biomarker development, and sepsis clinical trials; selective narrative review of the biomarker literature.
RESULTS: The utility of a biomarker is a function of the degree to which it adds value to the available clinical information in the domains of screening, diagnosis, risk stratification, and monitoring of the response to therapy. We identified needs for greater standardization of biomarker methodologies, greater methodologic rigor in biomarker studies, wider integration of biomarkers into clinical studies (in particular, early phase studies), and increased collaboration among investigators, pharmaceutical industry, biomarker industry, and regulatory agencies.
CONCLUSIONS: Biomarkers promise to transform sepsis from a physiologic syndrome to a group of distinct biochemical disorders. This transformation could aid therapeutic decision making, and hence improve the prognosis for patients with sepsis, but will require an unprecedented degree of systematic investigation and collaboration.
Keywords
Biological Markers/metabolism, Humans, Outcome and Process Assessment (Health Care), Predictive Value of Tests, Reproducibility of Results, Risk Assessment, Sepsis/diagnosis, Sepsis/metabolism
Pubmed
Web of science
Create date
03/02/2010 8:56
Last modification date
20/08/2019 16:21
Usage data